George Han, MD, PhD

Future Outlook for Atopic Dermatitis Treatments

Video content above is prompted by the following:

Please share final thoughts on the future of atopic dermatitis treatment with oral systemic agents.

Videos

The future of atopic dermatitis treatment with oral systemic agents is promising, with ongoing research and development of novel therapies. Advances in understanding the pathophysiology of atopic dermatitis have led to the identification of new therapeutic targets, resulting in the development of more effective and targeted treatments. These agents aim to provide better disease control, reduce side effects, and improve patient quality of life. The integration of personalized medicine approaches and biomarkers may further enhance treatment outcomes, offering tailored therapies based on individual patient profiles and disease characteristics.

Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.

Treatment Flexibility While on Abrocitinib in Atopic Dermatitis (JADE REGIMEN)

Please discuss data with oral JAK inhibitors as maintenance and rescue treatments.

Oral JAK inhibitors have emerged as promising agents in the management of various inflammatory and autoimmune conditions. As maintenance therapy, they offer a convenient oral administration route, potentially improving patient adherence compared to injectable biologics. These inhibitors target specific pathways involved in inflammation, providing a tailored approach to disease management. In rescue treatment scenarios, oral JAK inhibitors can rapidly modulate immune responses, offering a valuable option for patients experiencing disease flares. Ongoing research continues to refine their safety profile and optimize their therapeutic potential.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

Treatment Breaks and Rescue Treatments in Atopic Dermatitis

Given the chronic condition of atopic dermatitis, patients may choose or need to stop treatment during their treatment journey. How often do patients bring up the need for a treatment break?

How do you monitor patients during this period?

How do you educate and counsel patients about treatment breaks and rescue treatments?

Which patient is/is not a good candidate for it?

Patients with atopic dermatitis often consider or require treatment breaks due to the chronic nature of the condition. The frequency of patients initiating discussions about treatment breaks varies, influenced by individual circumstances and treatment responses. Monitoring during these periods involves regular follow-ups to assess disease activity and manage potential flares. Education and counseling focus on the importance of adherence, recognizing flare signs, and understanding rescue treatments. Ideal candidates for treatment breaks are those with stable disease and good self-management skills, while those with severe or poorly controlled symptoms may not be suitable.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Switching patients to JAK Inhibitors in Atopic Dermatitis in Clinical Practice

How would you rate dermatologists’ comfort in switching to a JAK inhibitor?

How often do you have to switch patients from biologics to JAK inhibitors?

What is your treatment strategy for this patient population?

Dermatologists' comfort in transitioning to JAK inhibitors varies, influenced by their familiarity with the drug class and patient-specific factors. The frequency of switching from biologics to JAK inhibitors depends on treatment response, side effects, and patient preferences. Treatment strategies for patients requiring JAK inhibitors involve a comprehensive assessment of disease severity, previous treatment history, and potential risks versus benefits. Dermatologists must weigh the efficacy and safety profiles of JAK inhibitors against other available therapies, considering individual patient needs and clinical outcomes to optimize treatment plans.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

George Han, MD, PhD

Articles